Potential Eye Disease Therapeutic Also Shows Promise as Antileukemic Drug

08:30 EST 19 Dec 2018 | Genetic Engineering News

Researchers at the Wellcome Sanger Institute, University of Cambridge, University of Nottingham and their collaborators have found that a compound in eye drops that was being developed for the treatment of an eye disease also targets an essential cancer gene and could kill leukemia cells without harming non-leukemic blood cells. The team’s study (“SRPK1 maintains acute myeloid […]

More From BioPortfolio on "Potential Eye Disease Therapeutic Also Shows Promise as Antileukemic Drug"